Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.96 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 8/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29394034 | 1.00 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL29355216 | 0.98 | GRM5 (1.00) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL103061 | 0.98 | GRM5 (1.00) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL24494372 | 0.85 | GRM5 (0.76) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL4713737 | 0.81 | GRM5 (0.71) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL4711639 | 0.81 | GRM5 (0.71) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| Hydrochloric Acid SCHEMBL27871332 | 0.81 | GRM5 (0.70) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL4712865 | 0.79 | GRM5 (0.68) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL6800311 | 0.79 | GRM5 (0.72) | NPC1RAB9ASMN1; SMN2LMNAPMP22 | |
| SCHEMBL4711543 | 0.79 | GRM5 (0.67) | NPC1RAB9ASMN1; SMN2LMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017208211-A1 | IDENTIFICATION OF DRUGS THAT INCREASE MUSCLE MASS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-07 | — | — | WO | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| EP-1900360-A1 | Homer a new target of treating psychiatric disorders | Abbott GmbH & Co. KG (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1140045-A2 | HOMER A NEW TARGET OF TREATING PSYCHIATRIC DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035430-A2 | HOMER A NEW TARGET OF TREATING PSYCHIATRIC DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | claimed |
| US-12441716-B2 | Compositions and methods for increasing muscle mass and oxidative metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250288581-A1 | BALIPODECT FOR TREATING OR PREVENTING AUTISM SPECTRUM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-3952849-B1 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | UNIV CALIFORNIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230270720-A1 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-115942979-A | MGLUR5 antagonist, marvorexant, for use in therapy to reduce opioid use | 诺华股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20220162198-A1 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006134111-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134112-A1 | SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060088834-A1 | Matrix analysis of gene expression in cells (magec) | BAIN GRETCHEN | 2006-04-27 | — | — | US | disclosed |
| EP-1497434-A4 | MATRIX ANALYSIS OF GENE EXPRESSION IN CELLS (MAGEC) | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1497434-A2 | MATRIX ANALYSIS OF GENE EXPRESSION IN CELLS (MAGEC) | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089589-A2 | MATRIX ANALYSIS OF GENE EXPRESSION IN CELLS (MAGEC) | MERCK & CO., INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441716-B2 | Compositions and methods for increasing muscle mass and oxidative metabolism | CPT1B, GYS1, PYGM | GRIN2B 781/4885HDAC6 1001/4885NPC1 3492/4885 |
| US-20230270720-A1 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | GRM5, GRIK5, GRM4 | GRIN2B 30/4885HDAC6 439/4885NPC1 1840/4885 |
| US-20220162198-A1 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM | CPT1B, GYS1, PYGM | GRIN2B 681/4885HDAC6 1031/4885NPC1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.